AIM
ALT icon

Acrospire Investment Management’s Altimmune ALT Stock Holding History

Acrospire Investment Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-194
Closed -$189K – 2190
2016
Q4 		$189K Buy
194
+76
+64% +$68.1K 0.08% 397
2016
Q3 		$103K Buy
118
+75
+174% +$58.8K 0.07% 525
2016
Q2 		$32K Buy
43
+23
+115% +$15.7K 0.02% 1338
2016
Q1 		$11K Buy
+20
New +$10.2K 0.01% 1715

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Acrospire Investment Management's ALT Position: Q1 2017 in Review

Acrospire Investment Management sold out of Altimmune (ALT) in Q1 2017, closing a stake of 194 shares — an estimated $189K sold.

Acrospire Investment Management first reported a position in ALT in Q1 2016 and held it in 4 quarters. The position peaked at $189K in Q4 2016. 71 funds tracked by Wall St. Rank hold ALT as of Q1 2017.

  • Acrospire Investment Management reported no remaining Altimmune position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 194 Altimmune shares in Q1 2017, an estimated $189K.
  • Acrospire Investment Management first reported a position in Altimmune in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Altimmune position peaked at $189K in Q4 2016.
  • 71 funds tracked by Wall St. Rank held Altimmune as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.